TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03760913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002 (Test): Part A, Single Ascending Dose
Description: Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002 (Test): Part B, Multiple Ascending Dose
Description: Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Placebo Part A, Single Ascending Dose
Description: Subcutaneous Injection: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Placebo Part B, Multiple Ascending Dose
Description: Subcutaneous Injection: Placebo x 5
Study: NCT02419703

Intervention type: DEVICE
Intervention: STAR™ Tumor Ablation System
Description: Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
Study: NCT02154295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infraredx Test Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infraredx Test Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infraredx Test Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infraredx Test Catheter
Study: NCT02598947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Exercise, behaviour change interventions and manual therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual therapy
Description: Exercise, behaviour change interventions and manual therapy
Study: NCT04335786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan (Diovan)
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d.
Study: NCT00216086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: biopsy per EUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: * Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Radiation
Description: Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery within 8 weeks following chemoradiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Adjuvant chemotherapy at investigator's discretion
Study: NCT02036112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ELAPE
Description: device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individual ELAPE
Description: device
Study: NCT04335786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
Study: NCT03450252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active pacing
Description: Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Back-up pacing
Description: Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
Study: NCT04147923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Floradapt Mature Immune Defense + Multivitamin
Description: The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Multivitamin
Description: No active ingredients + a multivitamin supplement
Study: NCT01939574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation Therapy
Description: * Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy
Description: * Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight.
Study: NCT04292652

Intervention type: PROCEDURE
Intervention: AAA surgery
Description: EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.

Intervention type: PROCEDURE
Intervention: AAA surgery
Description: EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
Study: NCT01593943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARM
Description: CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
Study: NCT03107247

Intervention type: DRUG
Intervention: Imaging Time
Description: Participants will be asked to be imaged at an additional time point.
Study: NCT06336395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral
Study: NCT04597788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low calorie diet program
Description: Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
Study: NCT03793738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior component separation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior component separation
Study: NCT00000116

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 15000 IU/d as retinyl palmitate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 15000 IU/d as retinyl palmitate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Description: 1200 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control fatty acid
Study: NCT00938249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monascus Garlic Fermented Extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04278755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone-Ethinyl Estradiol Oral Tablet
Description: 3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
Study: NCT03253367

Intervention type: OTHER
Intervention: Blood is obtained, mostly during routine venipuncture
Study: NCT01616030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee-extension strength training of the fractured limb
Description: Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
Study: NCT01932723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
Study: NCT02903030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltose (placebo)
Description: Maltose with a trace amount of silicon dioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome Extra Strength
Description: It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
Study: NCT00124761

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery + WBRT
Description: Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery + WBRT
Description: Radiosurgery - Marginal dose based on maximum tumour diameter
Study: NCT01318486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparin free dialysis technique
Description: Saline flushes or predilution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial
Description: Evodial dialyer
Study: NCT02424110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon beam coagulator ablation
Description: The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bipolar radiofrequency ablation
Description: The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: argon beam coagulator （American，Valleylab）
Description: Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bipolar radiofrequency (AtricuteTM)
Description: The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
Study: NCT01708148

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
Study: NCT04267458

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of sofuspovir containing DAA regien expected insult on kidney
Description: to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
Study: NCT04435132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL under fluoroscopy with the aid of the robotic device
Description: During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
Study: NCT03174834

Intervention type: OTHER
Group type: OTHER
Intervention: Bladder Stimulation technique
Description: The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
Study: NCT00627120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
Study: NCT03585257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25% IV albumin
Description: Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups.
Study: NCT01914198

Intervention type: OTHER
Intervention: Sleep apnea symptom survey
Description: Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
Study: NCT04212650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance-matched microcrystalline cellulose placebo
Study: NCT01118221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: structured exercise program
Study: NCT01096901

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight loss
Description: Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
Study: NCT02300532

Intervention type: OTHER
Intervention: No intervention
Study: NCT03253029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pure Encapsulations Branched Chain Amino Acid powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control group (no BCAAs provided)
Study: NCT01755013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
Study: NCT04258722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation Personnel
Description: Type of resuscitation team
Study: NCT05493436

Intervention type: DIAGNOSTIC_TEST
Intervention: MII pH-meter
Description: using multichannel impedance pH-meter

Intervention type: DIAGNOSTIC_TEST
Intervention: MII pH-meter
Description: using multichannel impedance pH-meter
Study: NCT03926780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: 38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium
Description: 38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
Study: NCT03786276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-WMR-Only
Description: Participants will spend up to 30 minutes in a VR-WMR environment during each training session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-only
Description: Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active VR-WMR
Description: Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
Study: NCT03826992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days
Study: NCT03187210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BeEAM Regimen
Description: standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM Regimen
Description: standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM Regimen
Description: standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
Study: NCT02956031

Intervention type: OTHER
Intervention: Screening
Description: Cervical specimen obtained using speculum examination and cervical collection bush.

Intervention type: OTHER
Intervention: Screening
Description: Cervical specimen obtained using speculum examination and cervical collection bush.

Intervention type: OTHER
Intervention: Screening
Description: Cervical specimen obtained using speculum examination and cervical collection bush.

Intervention type: OTHER
Intervention: Colposcopy
Description: Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.

Intervention type: OTHER
Intervention: Colposcopy
Description: Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.

Intervention type: OTHER
Intervention: Colposcopy
Description: Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.

Intervention type: PROCEDURE
Intervention: LLETZ
Description: The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).

Intervention type: PROCEDURE
Intervention: LLETZ
Description: The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).

Intervention type: PROCEDURE
Intervention: LLETZ
Description: The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
Study: NCT03073369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol 50000 UNT
Description: Oral Ergocalciferol 50000 IU once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo - one capsule once daily for 6 weeks
Study: NCT02469701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab and ablation